8-KEarnings & ResultsExhibits & Filings

Edwards Lifesciences Corp 8-K Report, Financial Results (Jul 24, 2025)

Filed July 24, 2025For Securities:EW

Summary

Edwards Lifesciences Corp (EW) has filed a Form 8-K reporting its financial results for the second quarter of 2025, as of July 23, 2025. The primary focus of this filing is the issuance of a press release detailing the company's performance during the quarter. Investors should refer to the furnished press release (Exhibit 99.1) for specific financial figures, including revenue, earnings per share, and any commentary on operational performance and outlook. While the 8-K itself does not contain the detailed financial data, it serves as the official notification of the release of this information. The press release is expected to provide insights into key growth drivers, segment performance (such as transcatheter aortic valve replacement - TAVR, and critical care), and any forward-looking guidance provided by the company. Investors should carefully review Exhibit 99.1 for a comprehensive understanding of Edwards Lifesciences' recent financial health and future expectations.

Key Highlights

  • 1Edwards Lifesciences filed an 8-K on July 23, 2025, announcing its Q2 2025 financial results.
  • 2The core of the filing is a press release (Exhibit 99.1) containing the detailed Q2 2025 financial performance.
  • 3Investors need to review Exhibit 99.1 for specific revenue, earnings, and operational metrics.
  • 4The filing indicates the event date for the results was July 23, 2025.
  • 5Information furnished under Item 2.02 is not considered 'filed' for purposes of the Securities Exchange Act of 1934.
  • 6The filing includes the Cover Page Interactive Data File in its exhibits.

Frequently Asked Questions

The actual financial results for the second quarter of 2025 are detailed in the press release furnished as Exhibit 99.1 to this Form 8-K. You will need to access this exhibit for specific figures on revenue, earnings, and other financial metrics.

This 8-K filing officially announces that Edwards Lifesciences has released its financial results for the second quarter of 2025. It directs investors to the accompanying press release for the detailed information.

The 8-K filing itself does not contain forward-looking guidance. However, the press release (Exhibit 99.1) that is furnished with this filing is the likely place where the company would provide any updated financial outlook or guidance for future periods.

Information furnished under Item 2.02 of an 8-K, such as financial results disclosed in a press release, is not considered legally 'filed' with the SEC. This means it is not subject to the same liabilities under Section 18 of the Exchange Act as information that is formally filed. However, it is still important for investors to review as it contains material company updates.